4.8 Article

Chromosome 3q26 Gain Is an Early Event Driving Coordinated Overexpression of the PRKCI, SOX2, and ECT2 Oncogenes in Lung Squamous Cell Carcinoma

期刊

CELL REPORTS
卷 30, 期 3, 页码 771-+

出版社

CELL PRESS
DOI: 10.1016/j.celrep.2019.12.071

关键词

-

资金

  1. National Institutes of Health/National Cancer Institute [R01 CA081436-22, R01 CA206267-04, R01 CA140290-05, R03 CA235189]
  2. Mayo Clinic Center for Biomedical Discovery Career Development Award
  3. American Cancer Society Research Scholar Award [RSG-18-201-01]
  4. Edward C. Kendall Fellowship in Biochemistry from the Mayo Clinic Graduate School

向作者/读者索取更多资源

Lung squamous cell carcinoma (LSCC) is a prevalent form of lung cancer exhibiting distinctive histological and genetic characteristics. Chromosome 3q26 copy number gain (CNG) is a genetic hallmark of LSCC present in >90% of tumors. We report that 3q26 CNGs occur early in LSCC tumorigenesis, persist during tumor progression, and drive coordinate overexpression of PRKCI, SOX2, and ECT2. Over-expression of PRKCI, SOX2, and ECT2 in the context of Trp53 loss is sufficient to transform mouse lung basal stem cells into tumors with histological and genomic features of LSCC. Functionally, PRKCI and SOX2 collaborate to activate an extensive transcriptional program that enforces a lineage-restricted LSCC phenotype, whereas PRKCI and ECT2 collaborate to promote oncogenic growth. Gene signatures indicative of PKC iota-SOX2 and PKC iota-ECT2 signaling activity are enriched in the classical subtype of human LSCC and predict distinct therapeutic vulnerabilities. Thus, the PRKCI, SOX2, and ECT2 oncogenes represent a multigenic driver of LSCC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据